The Contraceptive Drugs Market is projected to reach USD 300.41 billion by 2033, growing from USD 28.10 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 6.67% from 2023 to 2033. This market encompasses global sales of medications designed to prevent pregnancy, including oral contraceptives (birth control pills), injectables, skin patches, and vaginal rings. These contraceptives function through various mechanisms, such as inhibiting ovulation (the release of an egg from the ovary), thickening cervical mucus to impede sperm movement, or altering the uterine lining to prevent the implantation of a fertilized egg.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Product Type (Drugs, Devices, Intrauterine Devices (IUDs), Hormonal IUDs, Copper IUDs, Diaphragms, Others)
By End Users (Household, Hospitals, Clinic)
Key players
Bayer AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co. Inc.
Mylan N.V.
Allergan Plc
Agile Therapeutics
GlaxoSmithKline PLC
Johnson & Johnson
Novartis AG
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook